TY - JOUR
T1 - Use of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation
AU - Beckenstrom, Amy C.
AU - Coloma, Preciosa M.
AU - Dawson, Gerard R.
AU - Finlayson, Ailidh K.
AU - Malik, Asad
AU - Post, Anke
AU - Steiner, Michel Alexander
AU - Potenza, Marc N.
N1 - Funding Information:
Idorsia Pharmaceuticals Ltd. provided funding to support the preparation of this article. Dr. Potenza’s involvement was supported by the NIH grant R01 DK121551 .
Funding Information:
The authors thank Anne Sayers (MA(Cantab)) of Idorsia Pharmaceuticals Ltd. for providing editorial support, which was funded by Idorsia Pharmaceuticals Ltd. in accordance with Good Publications Practice (GPP 2022) guidelines.
PY - 2023/4/30
Y1 - 2023/4/30
N2 - Despite progress in understanding the pathological mechanisms underlying psychiatric disorders, translation from animal models into clinical use remains a significant bottleneck. Preclinical studies have implicated the orexin neuropeptide system as a potential target for psychiatric disorders through its role in regulating emotional, cognitive, and behavioral processes. Clinical studies are investigating orexin modulation in addiction and mood disorders. Here we review performance-outcome measures (POMs) arising from experimental medicine research methods which may show promise as markers of efficacy of orexin receptor modulators in humans. POMs provide objective measures of brain function, complementing patient-reported or clinician-observed symptom evaluation, and aid the translation from preclinical to clinical research. Significant challenges include the development, validation, and operationalization of these measures. We suggest that collaborative networks comprising clinical practitioners, academics, individuals working in the pharmaceutical industry, drug regulators, patients, patient advocacy groups, and other relevant stakeholders may provide infrastructure to facilitate validation of experimental medicine approaches in translational research and in the implementation of these approaches in real-world clinical practice.
AB - Despite progress in understanding the pathological mechanisms underlying psychiatric disorders, translation from animal models into clinical use remains a significant bottleneck. Preclinical studies have implicated the orexin neuropeptide system as a potential target for psychiatric disorders through its role in regulating emotional, cognitive, and behavioral processes. Clinical studies are investigating orexin modulation in addiction and mood disorders. Here we review performance-outcome measures (POMs) arising from experimental medicine research methods which may show promise as markers of efficacy of orexin receptor modulators in humans. POMs provide objective measures of brain function, complementing patient-reported or clinician-observed symptom evaluation, and aid the translation from preclinical to clinical research. Significant challenges include the development, validation, and operationalization of these measures. We suggest that collaborative networks comprising clinical practitioners, academics, individuals working in the pharmaceutical industry, drug regulators, patients, patient advocacy groups, and other relevant stakeholders may provide infrastructure to facilitate validation of experimental medicine approaches in translational research and in the implementation of these approaches in real-world clinical practice.
KW - Clinical trial
KW - Cognitive task
KW - Drug development
KW - Experimental medicine
KW - Orexin agonist
KW - Orexin antagonist
KW - Orexin system
KW - Performance-outcome assessment
KW - Psychiatry
UR - http://www.scopus.com/inward/record.url?scp=85149332523&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2023.105107
DO - 10.1016/j.neubiorev.2023.105107
M3 - Review article
C2 - 36828161
AN - SCOPUS:85149332523
SN - 0149-7634
VL - 147
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
M1 - 105107
ER -